Safety Study for Refractory or Relapsed Neuroblastoma With DFMO Alone and in Combination With Etoposide

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborators:
Cancer Prevention Pharmaceuticals, Inc.
University of Arizona
University of Hawaii
Information provided by (Responsible Party):
Giselle Sholler, Van Andel Research Institute
ClinicalTrials.gov Identifier:
NCT01059071
First received: January 26, 2010
Last updated: February 12, 2013
Last verified: February 2013
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: June 2016
  Estimated Primary Completion Date: June 2013 (Final data collection date for primary outcome measure)